Today: 17 May 2026
Browse Category

NASDAQ:MRK 1 March 2026

Merck stock heads into Monday with Keytruda, Welireg cancer data and FDA review dates on deck

Merck stock heads into Monday with Keytruda, Welireg cancer data and FDA review dates on deck

Merck shares rose 3.8% to $123.82 Friday, trading on heavy volume. The company reported Phase 3 trial results showing Keytruda-based combinations improved survival in ovarian and kidney cancers. The FDA set June 19 and Oct. 4, 2026, target dates for reviews of Keytruda and Welireg combinations in kidney cancer. Keytruda accounted for nearly half of Merck’s 2025 revenue, with major patents expiring in 2028.
1 March 2026
·

Stock Market Today

  • Nasdaq Eyes Nearly 24-Hour Trading; SEC Approves Extended Hours Proposal
    May 16, 2026, 11:18 PM EDT. Nasdaq received SEC approval to extend trading hours for NMS stocks and exchange-traded products (ETPs) from 16 to 23 hours daily, starting December 6, pending regulatory clearance. Trading will run in two sessions: Day Session from 4:00 AM to 8:00 PM ET and Night Session from 9:00 PM to 4:00 AM ET, with a one-hour pause for system maintenance. This change responds to global investor demand and the rise of crypto trading, which operates 24/7. The move could prompt other exchanges to extend hours. Experts question how to define a trading day's start and end given global market overlaps. Nasdaq's Giang Bui highlights that extended hours cater to worldwide investors accustomed to round-the-clock crypto markets, signaling shifts in traditional equity trading.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Go toTop